Skip to main content

Drug Safety

      RT @drdavidliew: Atypical patterns of HCQ retinopathy:
      - outside the central macula
      - missed by standard central macula
      3 years 2 months ago
      Atypical patterns of HCQ retinopathy: - outside the central macula - missed by standard central macula screening - 41x more likely in Asians! Lesson: screening with extramacular SD-OCT for Asian HCQ pts is so, so important. 41x over. @MGHrheumatology #ACR21 ABST0989 @RheumNow https://t.co/0w7ALHJDSW
      Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With…
      The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest…
      RT @Janetbirdope: How concerned should we be for #hydroxychloroquine retinopathy. >4000 pts prospectively followed. 1
      3 years 2 months ago
      How concerned should we be for #hydroxychloroquine retinopathy. >4000 pts prospectively followed. 1/2 w RA & 15% w #SLE. New risks Asian with pericentral pattern and overall. Length of time on use and ⬆️wt based dose per day & CKD all risks. Abst#0989 #ACR21 #ACRBest @RheumNow https://t.co/XTfdQpVC7H
      RT @drdavidliew: In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g.

      All pts
      3 years 2 months ago
      In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g. All pts in centre offered Fibroscan liver stifness associations: - age, BMI - not cumulative MTX dose maybe survival bias, but what we're doing now is fine! #ACR21 ABST0786 @RheumNow https://t.co/I6IhS3jhmC
      RT @AkhilSoodMD: Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks
      #ACR21 @RheumNow https://t.
      3 years 2 months ago
      Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks #ACR21 @RheumNow https://t.co/Dl5WPo7mmj
      RT @drdavidliew: This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion.

      RWE
      3 years 2 months ago
      This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion. RWE Cohort: HR 1.01 (0.83-1.22) RCT-dup Cohort: HR 1.19 (0.86-1.64) ORAL Surveillance: HR 1.48 (1.04-2.09) Interesting day 4 ahead! great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr
      RT @Yuz6Yusof: #ACR21 #Abstr0871 📢Argument against HCQ<5mg/kg dose from cardiac perspective in #lupus. A retrospec
      3 years 2 months ago
      #ACR21 #Abstr0871 📢Argument against HCQ<5mg/kg dose from cardiac perspective in #lupus. A retrospective study N=296 pts, 13% developed CV events.⬇️28% in risk of heart failure, arrhythmia/cardiac death per mg/kg of HCQ in non-smokers @RheumNow #ACRBest https://t.co/6ssd2159R1 https://t.co/tllPWLnFFj
      ×